The Midlands Therapeutics Review and Advisory Committee has published reviews of sitagliptin and inhaled insulin.
The review of sitagliptin suggests that the drug is suitable for prescribing in primary care but only after metformin and sulphonylureas as recommended in guidance from the National Institute for Health and Clinical Excellence (NICE).
The review of inhaled insulin suggests that the drug is not suitable for prescribing in primary care. This recommendation is based on the limited numbers of patients who would meet the strict NICE criteria for eligibility and the long-term safety concerns, especially regarding changes in lung function.
Action: Clinicians who treat diabetes in primary or secondary care will find these product reviews to be a useful summary of the currently available evidence.